Search the Newsreel

Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings

The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance

Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages

Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump

Bioventus Inc. (BVS) reported strong Q2 2026 results with a significant jump in net income and reaffirmed its full-year 2026 sales guidance of US$600 million to US$610 million. The company's investment narrative focuses on converting modest sales growth into higher profitability while managing debt. …

Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain

Bioventus (BVS) stock surged 13.7% following a strong Q2 earnings report, showcasing adjusted EBITDA of US$35 million on US$153.2 million revenue and healthy cash generation. While the company's profitability and cash flow are positive, concerns remain regarding its reliance on a narrow product set, …

Bioventus earnings beat, revenue fell short of estimates

Bioventus, Inc.: Bioventus Reports Second Quarter Financial Results

Bioventus Inc. reported strong second-quarter 2026 financial results, with reported revenue increasing 4% to $153.2 million and GAAP earnings per diluted share rising significantly to $0.47. The company reaffirmed its full-year 2026 guidance for revenue, Adjusted Diluted EPS, and cash from operations, and announced …

Earnings call transcript: Bioventus posts Q2 2026 EPS beat, shares slip premarket

Bioventus Shareholder Notice

Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's offering documents and public …

Bioventus (BVS) Q2 Earnings Meet Estimates

Bioventus Reports Second Quarter Financial Results

Bioventus Inc. reported strong second-quarter 2026 financial results, with reported revenue increasing 4% to $153.2 million and GAAP earnings per diluted share rising significantly to $0.47. The company reaffirmed its full-year 2026 guidance for revenue, Adjusted Diluted EPS, and cash from operations, and announced …

Bioventus (Nasdaq: BVS) posts Q2 profit surge and weighs strategic options

Bioventus Inc. (Nasdaq: BVS) reported a significant surge in Q2 2026 net income to $33.4 million, up from $7.5 million year-over-year, driven by strong net sales of $153.2 million and the removal of a deferred tax asset valuation allowance. The company reaffirmed its full-year …

Bioventus Q2 Earnings Call Highlights

Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BVS) 2026-08-05

Bioventus (NASDAQ:BVS) Releases FY 2026 Earnings Guidance

Bioventus (BVS) Earnings Date and Reports 2026 $BVS

Bioventus Starts Review After Unsolicited Acquisition Proposal

Bioventus Q2 Revenue Rises 4% as Strategic Review Begins

5 Growth Stocks That Pass Peter Lynch's Favorite Test

This article identifies five growth stocks that align with Peter Lynch's investment philosophy, combining valuation discipline with strong financial health and growth prospects. It explains a screening methodology using the P/E ratio, Piotroski F-score, and five-year earnings growth rate to find companies like National …

Bioventus Shareholder Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Bioventus's initial public offering documents …

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

BioNTech SE Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer ("CEO"), who will take office by February …

Guido Oelkers to step down as CEO of Sobi in the beginning of 2027

STOCKHOLM, Aug. 3, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces that Guido Oelkers has informed the Board of Directors that he has decided to step down as Chief Executive Officer of Sobi to take up another position outside Sobi. Guido …

Bioventus Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Bioventus made materially false …

Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth

Wall Street expects a year-over-year increase in earnings on higher revenues when Bioventus (BVS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

Bioventus schedules Aug. 5 call to discuss second-quarter results

BlackRock (BVS) discloses 3.4M-share, 5.02% passive stake in Bioventus

BlackRock, Inc. has disclosed a passive ownership stake of 5.02% in Bioventus Inc.'s Class A stock, totaling 3,404,523 shares. This information was reported via a Schedule 13G filing, indicating BlackRock holds sole voting power over 3,350,552 shares and sole dispositive power over all 3,404,523 …

Should Value Investors Buy Bioventus (BVS) Stock?

Bioventus (BVS) Upgraded to Buy: Here's Why

Swedish Orphan Biovitrum AB (BIOVF) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Revenue Growth: 29% at constant exchange rates. Adjusted EBITDA Margin: 35% for Q2. Total Net Sales: Just under SEK7.8 billion for the quarter. Geographic Revenue Growth: North America 33%, International markets 45%, Europe 23%. Product Performance: Strong contributions …

Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks

Bioventix Plc Actuals & Estimates (LSE:BVXP)

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates

Bioventix (LON:BVXP) Will Pay A Dividend Of £0.80